TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06226116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket preservation
Description: After the tooth extraction the investigator will select two sockets, one will be assigned as the experimental side and we will preserve it with cold-processed autologous dentin. The second will be designated the control group and we will only stabilize the blood clot.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placement of experimental implants
Description: After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.
Study: NCT00099658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide-protein conjugate vaccine
Description: Injection administered three times before the age of 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide-protein conjugate vaccine
Description: Injection administered three times before the age of 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide-protein conjugate vaccine
Description: Injection administered three times before the age of 24 weeks
Study: NCT02268825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose
Study: NCT03979885

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation counseling (Quitline)
Description: Quitline offers community-based counseling session with a cessation counselor.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation counseling (Quitline)
Description: Quitline offers community-based counseling session with a cessation counselor.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation counseling (Quitline)
Description: Quitline offers community-based counseling session with a cessation counselor.
Study: NCT06226116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of experimental implants
Description: After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: histological sample collection
Description: Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: histological sample collection
Description: Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long.
Study: NCT03852485

Intervention type: DEVICE
Intervention: SD-OCT
Description: Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures

Intervention type: DEVICE
Intervention: SD-OCT
Description: Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures

Intervention type: DEVICE
Intervention: SD-OCT
Description: Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures

Intervention type: DEVICE
Intervention: SD-OCT
Description: Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
Study: NCT04070521

Intervention type: OTHER
Intervention: Observational EEG Monitoring
Description: Subjects will be monitored with electroencephalogram (EEG) after arriving to the Emergency Department with suspected overdose
Study: NCT01617889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental powdered milk-based infant formula with an alternate fat blend
Description: formula to be consumed ad lib

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A powdered milk-based infant formula, standard fat blend
Description: formula to be consumed ad lib
Study: NCT00955097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity®
Description: Definity® injections given both pre-ablation and post-ablation
Study: NCT00689195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin powder
Description: oral capsules containing the investigational agent

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha extract
Description: 4.5% extract of ashwagandha
Study: NCT01362309

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: d-cycloserine.
Description: 50 mg administered on two occasions.
Study: NCT03547960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Guar gum
Description: Fibre supplement to be taken with each meal

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Placebo. Fibre supplement to be taken with each meal
Study: NCT01376115

Intervention type: DRUG
Intervention: Nelarabine
Study: NCT04362527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone 1 Mg/mL Solution for Injection
Description: Blinding procedure will be set up for the administration of the treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution for injection
Description: Blinding procedure will be set up for the administration of the treatment
Study: NCT00937703

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: paper support for glycaemia face to face visit at T4mounths

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVS
Description: patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDAphone
Description: Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
Study: NCT04362514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEPC - Multi-component exercise program related to cycling
Description: Structured and progressive multicomponent exercise program with and without bikes. Training period will last over 3 months with 8 sessions à 60 minutes. Training sessions will address motor competence (balance, strength, cycling skills and techniques) and cognitive skills required during cycling. Furthermore, fall-related psychological concerns will be addressed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HRP - health-related presentations
Description: HRP include 3 presentations on healthy aging (one per month) with a duration of 60 minutes
Study: NCT01102439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300 mg loading dose, then 75 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81 mg daily
Study: NCT01362309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-cycloserine.
Description: 50 mg administered on two occasions.
Study: NCT03979885

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
Description: Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
Description: Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
Study: NCT01102439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg daily
Study: NCT02489994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePrime
Description: The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
Study: NCT03278964

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orbital decompression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital decompression
Study: NCT00733863

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106
Study: NCT03237767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIE
Description: The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIE
Description: The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold.
Study: NCT03979885

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
Description: Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
Study: NCT02467504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hrIL-2 active
Description: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
Study: NCT03237767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIE
Description: The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIE
Description: The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery.
Study: NCT03591237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
Study: NCT01464658

Intervention type: PROCEDURE
Group type: OTHER
Intervention: panniculectomy
Description: surgery
Study: NCT03552575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
Study: NCT01052545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit-Feedback
Description: Applied as a post-prescription antimicrobial review based on established guidelines.
Study: NCT05081856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization with moduler medical equipment carring vehicle
Description: Mobilization of the patients was carried out with the vehicle in their modular vehicle.
Study: NCT03979885

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Financial incentives for smoking cessation
Description: Participants will receive financial incentives for bioconfirmed smoking cessation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Financial incentives for use of evidence-based smoking cessation therapies
Description: Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
Study: NCT02870101

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nucleic acid amplification test 1 for NG and CT
Description: A combination test using real-time PCR to detect DNA from NG and CT.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nucleic acid amplification test 2 for NG and CT
Description: A combination test using target amplification to detect RNA from NG and CT.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nucleic acid amplification test 3 for NG and CT
Description: A combination test using real-time PCR to detect DNA from NG and CT.
Study: NCT02768519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTS167IV
Description: diluted to final concentration with cherry syrup

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cherry syrup
Study: NCT01795313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A2 restricted synthetic tumor antigen
Study: NCT01237236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Study: NCT01393639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 1 mg tablet once daily (QD) for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 5 mg tablet once daily (QD) for 8 weeks
Study: NCT01795313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Study: NCT01393639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 10 mg tablet once daily (QD) for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 15 mg tablet once daily (QD) for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 5 mg capsule once daily for 8 weeks
Study: NCT01795313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT04015050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: milk based infant formula
Description: Cows milk ased infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk based infant formula
Description: Cows milk ased infant formula
Study: NCT02467504

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hrIL-2 placebo
Description: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Methotrexate (oral administration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Methotrexate (oral administration)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic Acid (oral administration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Folic Acid (oral administration)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxoprofen
Description: Loxoprofen (oral administration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loxoprofen
Description: Loxoprofen (oral administration)
Study: NCT01393639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 10 mg capsule once daily for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (tablet or capsule) once daily (QD) for 8 weeks
Study: NCT01966224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Description: Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Description: Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Description: Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose.
Study: NCT04459741

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary salt (Sodium chloride)
Description: Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary salt (Sodium chloride)
Description: Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary salt (Sodium chloride)
Description: Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary salt (Sodium chloride)
Description: Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.
Study: NCT02163265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
Study: NCT01916044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Measure of Uterine Segment by Ultrasound
Study: NCT04241471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incision and loop drainage
Description: incision and loop drainage utilizing the rolled ring of a sterile glove technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional incision and drainage (I&D)
Description: traditional incision and drainage (I\&D)